When does Eliquis’ core patent run out?
The key U.S. patents covering apixaban (Eliquis) were filed in the mid‑2000s. A 20‑year term from a 2007 filing puts the principal patent expiring in 2027. A related formulation patent filed in 2008 would expire a year later, in 2028. These dates are the earliest that generic versions could legally enter the U.S. market, assuming no additional term extensions or secondary patents are in force.
Which patents actually protect Eliquis?
Pfizer and Allergan (now Bausch & Lomb) hold a bundle of patents covering apixaban’s active ingredient, its formulation, and its method of delivery. The main ones cited in the U.S. patent docket are:
- US 6,792,398 (active moiety), filed 2007, expires 2027.
- US 7,139,428 (extended‑release formulation), filed 2008, expires 2028.
Additional secondary patents on excipients and manufacturing processes may extend exclusivity slightly but are unlikely to delay generics beyond the 2027–2028 window.
Can generics hit the market before the 2027 date?
Generic manufacturers must wait until the primary patents expire unless they can prove a different formulation that does not infringe the existing claims or they can file a challenging patent infringement action. In the U.S., the FDA’s “Abbreviated New Drug Application” (ANDA) process requires proof of patent non‑infringement or allowance of a “patent challenge” before approval. Because the core patents are still in force, generics are unlikely to launch until 2027‑2028 at the earliest.
What about international patents?
Eliquis is protected by patents worldwide. Many of the same filings have 20‑year terms, but some countries grant extra protection for formulation patents, which could extend exclusivity into the early 2030s in certain markets. The European Union, Canada, and Australia all list similar patent expiry dates in their public databases.
Will competitors try to sidestep the patents?
Biologics and other anticoagulants (e.g., rivaroxaban, dabigatran) continue to compete on efficacy, safety, and dosing schedules. Some companies explore “biosimilar” versions of other anticoagulants, but these do not affect Eliquis’ patents directly. The main competitive threat will be a generic apixaban once the patents expire.
Are there any regulatory hurdles that could delay generics?
Beyond patent expiry, the FDA requires generics to demonstrate bioequivalence, which can involve extensive clinical testing. Even after patents lapse, a generic manufacturer may face a 12‑month “patent interference” period before the FDA can issue an ANDA. Therefore, the earliest practical launch window is around late 2027.
What does the 2027 expiration mean for patients?
When the patents lapse, generic apixaban could become available at a lower cost, improving affordability for patients who require long‑term anticoagulation. However, any price drop would depend on market competition and how many manufacturers are ready to file ANDAs.
Where can you track the exact patent status?
The U.S. Patent and Trademark Office (USPTO) and Google Patents provide up‑to‑date status on each filing, including renewal payments and current term. Checking the USPTO Patent Full-Text and Image Database (PatFT) or Google Patents with the application number gives the precise expiration date and any pending claims.
Sources
1. U.S. Patent US 6,792,398 – “Apixaban” – filing 2007, term 2027.
2. U.S. Patent US 7,139,428 – “Extended‑release formulation” – filing 2008, term 2028.
3. Wikipedia entry on Apixaban – overview of patent filings.
4. FDA “Eliquis” drug approval page – information on generics pathway.